UK Approval For MSD's COVID-19 Pill Molnupiravir Is A World First
Brand Name To Be Lagevrio
Executive Summary
The UK has led the way in granting a marketing authorization for the oral coronavirus treatment, which could help cut hospitalizations and deaths by half.
You may also be interested in...
UK Nod For Pfizer’s COVID-19 Oral Treatment
Pfizer’s Paxlovid is the second take-at-home COVID-19 treatment approved for use in the UK.
Coronavirus Notebook: Molnupiravir EU Approval Likely By Year End, Special CHMP Session Due On Comirnaty in 5 to 11-year-olds
The EMA is assessing the Janssen vaccine as a booster, and Switzerland is evaluating the use of the Pfizer/BioNTech and Moderna COVID-19 vaccines in younger age groups. The WHO has announced the first voluntary global license on a COVID-19 antibody detection technology.
Ildong Joins Oral COVID-19 Drug Race Via Shionogi Partnership
Ildong has become the latest Korean pharma firm to start developing an oral COVID-19 drug in the country, potentially competing with Merck and Pfizer’s candidates which are now under approval review locally. The latest co-development deal is also set to expand the market prospects for the antiviral's Japanese originator.